Bankrupt Sangamo sells Fabry gene therapy to PTC and prion program to Lilly for $161M

Sangamo Therapeutics, currently in Chapter 11 bankruptcy, has agreed to divest its Fabry disease gene therapy and several other platforms to raise cash for the restructuring.

PTC Therapeutics emerged as the winning bidder for the investigational Fabry gene therapy isaralgagene civaparvovec, agreeing to pay $111 million at closing with up to $100 million in milestone payments.

Eli Lilly will acquire Sangamo’s zinc‑finger, capsid delivery and molecular integrase platforms along with its prion disease program for $50 million.

Other interested parties will purchase select Sangamo tools and equipment for roughly $2.55 million. The transactions remain subject to final court approval, with total proceeds expected around $163.55 million plus future milestones.